Dr. Anand Veeravagu, MD

Dr. Veeravagu practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Veeravagu's NPI, 1386818284, was assigned on April 22, 2008. Dr. Veeravagu graduated from Stanford University School Of Medicine in 2009. Dr. Veeravagu holds California license A113373.

Dr. Veeravagu's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Veeravagu's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. Dr. Veeravagu is also affiliated with Santa Clara Valley Medical Center. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Veeravagu to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account. Dr. Veeravagu's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Veeravagu practices, 5 sites in all. Vendor and product names are available with a free account.

Neurological surgery is Dr. Veeravagu's primary specialty in the NPI Registry, under taxonomy code 207T00000X. Dr. Veeravagu is board certified in neurological surgery by the American Board of Neurological Surgery. Dmand AI has Dr. Veeravagu's licenses on file in 5 states: California, Nevada, Alaska, Hawaii and Oregon.

Dmand AI lists back and neck pain treatment without fusion, craniotomy, lower back pain, muscle pain, fibromyalgia, and limb pain, neck pain and spine problems, spinal fusion and thoracic spine disorders among the conditions Dr. Veeravagu treats.

CMS data shows 1,002 Medicare services from Dr. Veeravagu across 20 procedure codes in 2024, for 396 Medicare patients. Medicare paid $290,446 for them.

CMS counts 396 Medicare patients who saw Dr. Veeravagu in 2024. The largest group is 65 to 74, with 196 patients. 75% of them have arthritis, and 75% have high blood pressure. 21% are also on Medicaid. Their average risk score is 1.40, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Veeravagu's median patient age at 64, with 48% women.

In 2024, Dr. Veeravagu wrote 20 Medicare Part D claims. 95% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $671 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Veeravagu for performance year 2024, reported as part of a group. Dr. Veeravagu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Veeravagu as offering telehealth. CMS counts 410 procedures of spinal fusion by Dr. Veeravagu, more than 98% of the clinicians it reports for that procedure.

Dmand AI links 165 papers to Dr. Veeravagu, published from 2006 to 2025. 2024 was the busiest year, with 18. The most frequent topics are Postoperative Complications, Spinal Fusion and Neurosurgical Procedures. Dr. Veeravagu has published most often in World Neurosurg. Dr. Veeravagu's most frequent co-authors are John Kevin Ratliff, MD, Martin Nikolaus Stienen, MD and Atman Mukesh Desai, MD.

CMS Open Payments shows 1,069 general payments to Dr. Veeravagu from 23 drug and device companies from 2016 to 2025. Royalties and licenses make up the largest share, 49% of the total. Nuvasive, Inc. paid the most, $1,038,031.

Dr. Veeravagu graduated from Stanford University School Of Medicine in 2009. Dr. Veeravagu is a member of CNS.

Dr. Veeravagu is in network with 10 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.